Capricor Defends Deramiocel Data Ahead of FDA Advisory Meeting — Capricor Therapeutics, Inc.

Event summary

Capricor Therapeutics previews its FDA Advisory Committee meeting on July 29, 2026, for Deramiocel's Biologics License Application (BLA).
The company disputes the FDA’s reliance on outdated SAP version 1.1, arguing that Phase 3 HOPE-3 results show statistically significant benefits.
Deramiocel is an investigational cell therapy targeting Duchenne muscular dystrophy (DMD), a rare disease with high unmet medical need.

The big picture

Capricor’s defense of its clinical data highlights the tension between biotech innovation and stringent regulatory standards. The outcome of this FDA meeting will influence not only Deramiocel’s trajectory but also broader industry dynamics in rare disease treatments, where cell therapies face both high scientific promise and rigorous approval hurdles.

What we're watching

Regulatory Scrutiny: How the FDA’s reliance on outdated data may impact Deramiocel’s approval prospects.
Clinical Validation: Whether Capricor can sustain its Phase 3 HOPE-3 results under regulatory and market scrutiny.
Market Differentiation: The pace at which Deramiocel can establish itself as a leading therapy for Duchenne muscular dystrophy.